Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis

BACKGROUND The circulating metabolome is altered in multiple sclerosis (MS), but its prognostic capabilities have not been extensively explored. Lipid metabolites might be of particular interest due to their multiple roles in the brain, as they can serve as structural components, energy sources, and bioactive molecules. Gaining a deeper understanding of the disease may be possible by examining the lipid metabolism in the periphery, which serves as the primary source of lipids for the brain. OBJECTIVE To determine if altered serum lipid metabolites are associated with the risk of relapse and disability in children with MS. METHODS We collected serum samples from 61 participants with pediatric-onset MS within 4 years of disease onset. Prospective longitudinal relapse data and cross-sectional disability measures (Expanded Disability Status Scale (EDSS)) were collected. Serum metabolomics was performed using untargeted liquid chromatography and mass spectrometry. Individual lipid metabolites were clustered into pre-defined pathways. The associations between clusters of metabolites and relapse rate and EDSS score were estimated utilizing negative binomial and linear regression models, respectively. RESULTS We found that serum acylcarnitines (relapse rate: normalized enrichment score (NES) = 2.1, q = 1.03E-04; EDSS: NES = 1.7, q = 0.02) and poly-unsaturated fatty acids (relapse rate: NES = 1.6, q = 0.047; EDSS: NES = 1.9, q = 0.005) were associated with higher relapse rates and EDSS, while serum phosphatidylethanolamines (relapse rate: NES = -2.3, q = 0.002; EDSS: NES = -2.1, q = 0.004), plasmalogens (relapse rate: NES = -2.5, q = 5.81E-04; EDSS: NES = -2.1, q = 0.004), and primary bile acid metabolites (relapse rate: NES = -2.0, q = 0.02; EDSS: NES = -1.9, q = 0.02) were associated with lower relapse rates and lower EDSS. CONCLUSION This study supports the role of some lipid metabolites in pediatric MS relapses and disability.

[1]  D. Wishart,et al.  Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials , 2022, Pharmacological Reviews.

[2]  P. Bhargava,et al.  Intermittent calorie restriction alters T cell subsets and metabolic markers in people with multiple sclerosis , 2022, medRxiv.

[3]  Chang Liu,et al.  Medium & long-chain acylcarnitine’s relation to lipid metabolism as potential predictors for diabetic cardiomyopathy: a metabolomic study , 2021, Lipids in health and disease.

[4]  R. Epand,et al.  Plasmalogens and Chronic Inflammatory Diseases , 2021, Frontiers in Physiology.

[5]  K. Waddington,et al.  Disrupted Lipid Metabolism in Multiple Sclerosis: A Role for Liver X Receptors? , 2021, Frontiers in Endocrinology.

[6]  P. Bhargava,et al.  Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism , 2021, medRxiv.

[7]  G. Rosania,et al.  L-Carnitine and Acylcarnitines: Mitochondrial Biomarkers for Precision Medicine , 2021, Metabolites.

[8]  Jerry L Prince,et al.  Serum ceramide levels are altered in multiple sclerosis , 2020, Multiple sclerosis.

[9]  P. Domingues,et al.  Serum phospholipidomics reveals altered lipid profile and promising biomarkers in multiple sclerosis. , 2020, Archives of biochemistry and biophysics.

[10]  R. Hohlfeld,et al.  Plasma lipidomics of monozygotic twins discordant for multiple sclerosis , 2020, Annals of clinical and translational neurology.

[11]  P. Bhargava,et al.  Metabolomics in multiple sclerosis disease course and progression , 2020, Multiple sclerosis.

[12]  M. Hasan,et al.  Identification of Altered Metabolic Pathways during Disease Progression in EAE Mice via Metabolomics and Lipidomics , 2019, Neuroscience.

[13]  M. Inglese,et al.  A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis. , 2019, Brain : a journal of neurology.

[14]  R. Pamplona,et al.  Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis , 2019, Scientific Reports.

[15]  Alonso Barrantes-Freer,et al.  Myelin in the Central Nervous System: Structure, Function, and Pathology. , 2019, Physiological reviews.

[16]  L. Newby,et al.  Metabolome-based signature of disease pathology in MS. , 2019, Multiple sclerosis and related disorders.

[17]  P. Bhargava,et al.  Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course , 2018, Annals of clinical and translational neurology.

[18]  Yusuf A. Hannun,et al.  Sphingolipids and their metabolism in physiology and disease , 2017, Nature Reviews Molecular Cell Biology.

[19]  E. Waubant,et al.  Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[20]  Richard P. Bazinet,et al.  Polyunsaturated fatty acids and their metabolites in brain function and disease , 2014, Nature Reviews Neuroscience.

[21]  P. Bhargava,et al.  Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. , 2014, Brain : a journal of neurology.

[22]  S. Adams,et al.  Acylcarnitines activate proinflammatory signaling pathways. , 2014, American journal of physiology. Endocrinology and metabolism.

[23]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[24]  H. Kinney,et al.  Aberrant Upregulation of Astroglial Ceramide Potentiates Oligodendrocyte Injury , 2012, Brain pathology.

[25]  G. Schmitz,et al.  Plasmalogens the neglected regulatory and scavenging lipid species. , 2011, Chemistry and physics of lipids.

[26]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[27]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[28]  L. Horrocks,et al.  Modulation of inflammation in brain: a matter of fat , 2006, Journal of neurochemistry.

[29]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Healy,et al.  Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. , 2009, Archives of neurology.